Search results
Results From The WOW.Com Content Network
1 Introduction. Breast cancer (BC) is the second most common cancer and the leading cause of female mortality globally. Approximately 15%–20% of BC patients overexpress human epidermal growth factor receptor 2 (HER2) (Loibl and Gianni, 2017).Patients with HER2-positive (HER2+) BC have a more aggressive disease course, leading to a poorer prognosis than patients with other subtypes of BC ...
Treatment for HER2 positive breast cancer depends on the tumor’s size. Patients with tumors smaller than 2 centimeters, with no lymph nodes affected, will undergo surgery first, followed by chemotherapy and a single antibody targeting the HER2 protein known as trastuzumab (Herceptin).
The combination of trastuzumab and pertuzumab and a single-agent chemotherapeutic should be the standard first-line treatment for most patients with HER2-positive advanced breast cancer.
Traditional chemotherapy, radiation and surgery still play an important role in the treatment of HER2-positive cancers. These treatments often are used along with newer treatments that target HER2-positive cancer in slightly different ways. There are three main types of HER2-targeted therapies.
HER2-positive (HER2+) breast cancer affects some people who have invasive breast cancer. This is a fast-growing cancer that can quickly spread from your breast to other areas of your body. Healthcare providers can treat and often cure this cancer if it’s caught early on.
In this Review, we describe key steps in the development of the modern paradigm for the treatment of HER2-positive advanced-stage breast cancer, including selecting and sequencing...
2. Neoadjuvant Treatment. Neoadjuvant HER2-based therapy is typically used (as in other subtypes) in locally advanced breast cancer (Stage IIb with T3 disease, or Stage III), or in patients with an earlier stage HER2+ disease who desire breast conserving therapy, have limited axillary nodal involvement (N1) (which could potentially be converted to node-negative disease and therefore result in ...
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to...
Hormone-receptor positive (HR +) and human epidermal growth factor receptor 2 (HER2) negative breast cancer (BC) is the most common subset of BC world-wide, accounting for approximately 65–70% of cases [].In 2023 in the U.S., it is estimated there will be 297,790 new cases of female BC, with HR + BC comprising the majority at an age-adjusted rate of 87.2 new cases per 100,000 women [].
The National Comprehensive Cancer Network (NCCN) also has a video on how some of these HER2-targeted therapies work.. Monitoring metastatic breast cancer. You’ll be monitored (checked) regularly with scans to see if the cancer is responding to treatment. If the treatment is no longer working, or you’re having a lot of side effects, your health care provider will change your treatment or ...